151 related articles for article (PubMed ID: 25003664)
1. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study.
Tian C; Sargent DJ; Krivak TC; Powell MA; Gabrin MJ; Brower SL; Coleman RL
Br J Cancer; 2014 Aug; 111(5):843-50. PubMed ID: 25003664
[TBL] [Abstract][Full Text] [Related]
2. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer.
Rutherford T; Orr J; Grendys E; Edwards R; Krivak TC; Holloway R; Moore RG; Puls L; Tillmanns T; Schink JC; Brower SL; Tian C; Herzog TJ
Gynecol Oncol; 2013 Nov; 131(2):362-7. PubMed ID: 23954900
[TBL] [Abstract][Full Text] [Related]
3. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
4. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.
Gallion H; Christopherson WA; Coleman RL; DeMars L; Herzog T; Hosford S; Schellhas H; Wells A; Sevin BU
Int J Gynecol Cancer; 2006; 16(1):194-201. PubMed ID: 16445633
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
6. In vitro chemoresponse in metachronous pairs of ovarian cancers.
Dalton HJ; Fiorica JV; Edwards RP; Benjamin I; Rocconi RP; Recio FO; Lovecchio JL; Burrell MO; Shahin MS; Grendys EC; Wang D; Wang T; Monk BJ
Anticancer Res; 2014 Dec; 34(12):7191-6. PubMed ID: 25503148
[TBL] [Abstract][Full Text] [Related]
7. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
9. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
Previs R; Leath CA; Coleman RL; Herzog TJ; Krivak TC; Brower SL; Tian C; Secord AA
Gynecol Oncol; 2015 Aug; 138(2):267-71. PubMed ID: 26037898
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
Plamadeala V; Kelley JL; Chan JK; Krivak TC; Gabrin MJ; Brower SL; Powell MA; Rutherford TJ; Coleman RL
Gynecol Oncol; 2015 Jan; 136(1):94-8. PubMed ID: 25462203
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
13. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Colombo N; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Meunier J; Cameron T; Maloney L; Goble S; Bedel J; Ledermann JA; Coleman RL
Gynecol Oncol; 2020 Oct; 159(1):101-111. PubMed ID: 32861537
[TBL] [Abstract][Full Text] [Related]
14. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
15. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.
Loizzi V; Chan JK; Osann K; Cappuccini F; DiSaia PJ; Berman ML
Am J Obstet Gynecol; 2003 Nov; 189(5):1301-7. PubMed ID: 14634558
[TBL] [Abstract][Full Text] [Related]
17. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.
Kurbacher CM; Cree IA; Bruckner HW; Brenne U; Kurbacher JA; Müller K; Ackermann T; Gilster TJ; Wilhelm LM; Engel H; Mallmann PK; Andreotti PE
Anticancer Drugs; 1998 Jan; 9(1):51-7. PubMed ID: 9491792
[TBL] [Abstract][Full Text] [Related]
18. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
